Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2021.768128 Oncology Correction Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis Meng Jun 1 † Wu XiaoQin 2 † Sun Zhen 3 Xun RenDe 2 Liu MengSi 3 Hu Rui 3 Huang JianChao 2 * 1 Molecular Genetics Laboratory, Suining Central Hospital, Suining, China 2 Department of Neurosurgery, The First Affiliated Hospital, University of South China, Hengyang, China 3 Hengyang Medical College, University of South China, Hengyang, China

Edited and reviewed by: Sairah Ahmed, University of Texas MD Anderson Cancer Center, United States

*Correspondence: JianChao Huang, literatusyanyun@163.com

†These authors have contributed equally to this work and share first authorship

This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology

 07 10 2021 2021 11 768128 31 08 2021 08 09 2021 Copyright © 2021 Meng, Wu, Sun, Xun, Liu, Hu and Huang 2021 Meng, Wu, Sun, Xun, Liu, Hu and Huang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis By Meng J, Wu X, Sun Z, Xun R, Liu M, Hu R and Huang J (2021). Front. Oncol. 11:698607. doi: 10.3389/fonc.2021.698607. chimeric antigen receptor T-cell product CAR-T cell therapy immunotherapy lymphoma leukemia hematologic malignancy efficacy safety

In the original article, there were mistakes in Table 2 as published. We collected data with reference to both the conference abstract version and the full-text published version of the TRANSCEND NHL 001 trial conducted by Abramson et al. (1, 2); in Table 2 , we showed the data from the conference abstract version, which should be changed to the full-text version. The rest of the paper, including the meta-analysis and the systematic review section, was run with data from the full-text version of the TRANSCEND NHL 001 trial and is therefore unaffected. In addition, two footnotes were ignored in Table 2 . The corrected Table 2 appears below.

Characteristics of included studies.

First Author Year No. Median age (range)-yr Histological type CAR-T type Efficacy evaluation Scale Toxicity evaluation (grade≥3) Scale (CRS/ICANS) Ref
Schuster 2018 111 56 (22–76) DLBCL tisa-cel CR: 37/93PR: 11/93 Lugano CRS: 24/111ICANS: 13/111 Penn/CTCAE 4.03, MDRA 20.1 17
Schubert 2020 21 52 (20-68) 16 DLBCL, 3 PMBCL, 1 DHL, 1 tFL axi-cel CR: 9/21PR: 10/21 Lugano CRS: 0/21ICANS: 6/21 ASTCT/ASTCT 22
Pinnix 2020 124 60 (18-85) 95 DLBCL, 20 tFL, 9 PMBCL axi-cel CR: 60/124PR: 36/124 Lugano CRS: 11/124ICANS: 49/124 ASTCT, CARTOX/ASTCT, CARTOX 23
Nastoupil 2020 298 60 (21-83) 203 DLBCL, 76 tFL, 19 PMBCL axi-cel CR: 175/275PR: 50/175 Lugano CRS: 19/275ICANS: 85/275 CARTOX, Lee/CARTOX, CTCAE 4.03 24
Neelapu 2017 101 58 (23–76) 77 DLBCL, 16 tFL, 8 PMBCL axi-cel CR: 55/101PR: 28/101 IWGRC CRS: 13/101ICANS: 28/101 Lee/CTCAE 4.03 19
Locke 2017 7 46 (29-69) DLBCL axi-cel CR: 4/7PR: 1/7 IWGRC CRS: 1/7ICANS: 4/7 Lee/CTCAE 4.03 25
Jain 2019 4 56 (38-66) DLBCL axi-cel CR: 2/4PR: 1/4 NP CRS: 0/4ICANS: 0/4 NP/NP 26
Abbasi 2020 10 66 (55–77) DLBCL axi-cel CR: 8/10PR: 0/10 NP CRS: 1/10ICANS: 3/10 ASTCT/ASTCT 27
Garfall 2018 10 61 (48-68) MM tisa-cel CR: 6/10† PR: 2/10 IMWGRC CRS: 0/10ICANS: 0/10 NP/NP 28
Maude 2018 75 11 (3-23) ALL tisa-cel CR: 61/75PR: 0/75 Independent scale CRS: 35/75ICANS: 10/75 Penn/CTCAE 4.03 29
Maude 2014 30 14 (5-60) ALL tisa-cel CR: 27/30PR: 0/30 Independent scale CRS: 8/30 ICANS: NP Independent scale/NP 30
Schuster 2017 28 58 (25-77) 14 DLBCL14 FL tisa-cel CR: 16/28PR: 2/28 1999 IWGRC CRS: 5/28ICANS: 3/28 Penn/NP 31
Frigault 2019 8 50 (17-79) 5 DLBCL, 2 HGBCL, 1 PMBCL tisa-cel CR: 2/8PR: 2/8 NP CRS: 0/8ICANS: 0/8 Lee, ASTCT/Lee, ASTCT 32
Sim 2019 11 NP 8 DLBCL, 3 tFL, axi-cel CR: 5/11PR: 4/11 Lugano CRS: 1/11ICANS: 3/11 CTCAE 5.0/CTCAE 5.0 33
Porter 2015 14 66 (51-78) CLL tisa-cel CR: 4/14PR: 4/14 IWG on CLL RC CRS: 7/14ICANS: 1/14 Penn/CTCAE 3.0 34
Shah 2018 7 NP 3 DLBCL, 4 FL tisa-cel CR: 3/7PR: 2/7 Lugano CRS: NPICANS: NP NP/NP 35
Wright 2020 31 NP 26 DLBCL, 5 tFL 18 axi-cel, 13 tisa-cel CR: 11/27PR: 3/27 Lugano CRS: 6/31ICANS: 4/31 Penn/NP 36
Jacobson 2020 122 62 (21-79) 57 DLBCL, 33 tFL, 17 HGBCL, 8 PMBCL, 5 TMZL, 2 RS axi-cel CR: 61/122PR: 24/122 Lugano CRS: 19/122ICANS: 43/122 Lee/CTCAE 4.03 37
Abramson 2020 269 63 (54-70) 215 DLBCL, 36 HGBCL, 15 PMBCL, 3 FL3B liso-cel CR: 136/256PR: 50/256 Lugano CRS: 6/269ICANS: 27/269 Lee/CTCAE 4.03 16
Fehse 2019 10 56 (24-79) 7 DLBCL, 3 PMBCL axi-cel CR: 2/10PR: 5/10 NP CRS: 2/10ICANS: 1/10 ASTCT/ASTCT 38
Gupta 2019 78 60+-13※ DLBCL 69 axi-cel, 9 tisa-cel CR+PR: 43/78* NP CRS: 10/78ICANS: 22/78 CTCAE 5.0, Lee/CTCAE 5.0 39
Korell 2020 25 54 (20-68) 24 DLBCL, 1 PMBCL axi-cel CR: 9/25PR: 10/25 Lugano CRS: NPICANS: NP NP/NP 40
Frey 2019 35 34 (21-70) ALL tisa-cel CR: 24/35PR: 0/35 Independent scale CRS: 25/35ICANS: 2/35 Penn/CTCAE 4.03 41
Sesques 2020 61 59 (27-75) 38 DLBCL, 18 PMBCL, 4 tFL, 1 TMZL 28 axi-cel, 33 tisa-cel CR: 28/61PR: 9/61 Lugano CRS: 5/61ICANS: 6/61 ASTCT/ASTCT 42
Holtzman 2020 45 60 (26-75) 35 DLBCL, 3 PMBCL, 7 tFL axi-cel CR: 22/45PR: NP NP CRS: NPICANS: 18/45 NP/CTCAE 4.03 43
Strati 2020 100 60 (18-85) LBCL (Including 77 DLBCL) axi-cel CR: NPPR: NP Lugano CRS: 9/100ICANS:41/100 CARTOX/CARTOX 44
Faramand 2020 75 63 (23-79 50 DLBCL, 25 Transformed Indolent lymphomas axi-cel CR: 36/68PR: 29/68 Lugano CRS: 12/75ICANS: 23/75 ASTCT/CARTOX, ASTCT, CTCAE v4.03 45
Kittai 2020 9 64 (40-77) RS axi-cel CR: 8/8PR: 5/8 Lugano CRS: 1/9ICANS: 3/9 ASTCT/ASTCT 46
Deng 2020 24 58 (24-74) 16 DLBCL, 6 tFL, 2 PMBCL axi-cel CR: NPPR: NP NP CRS: 4/24ICANS: 12/24 NP/NP 47
Dean 2020 96 64 (19-79) 47 DLBCL, 15 HGBCL, 5 PMBCL, 29 NP axi-cel CR: 74/96PR: 63/96 NP CRS: 9/96ICANS: 28/96 Lee/CTCAE 4.03 48
Sermer 2020 69 63 (19-85) DLBCL 47 axi-cel, 22 tisa-cel CR: 50/69PR: 36/69 Lugano CRS: NPICANS: NP NP/NP 49
Wudhikarn 2020 60 63 (20-86) DLBCL 43 axi-cel, 17 tisa-cel CR: NPPR: NP NP CRS: 7/60ICANS: 13/60 NP/NP 50
Rubin 2020 204 60+-12※ Inexact# axi-cel CR: NPPR: NP NP CRS: NPICANS: 51/204 NP/CTCAE 4.03 51

CR, complete response; PR, partial response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; DLBCL, diffuse large B cell lymphoma; FL/tFL, follicular lymphoma or transformed follicular; PMBCL, primary mediastinal B-cell lymphoma; HGBCL, high-grade B cell lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CAR-T, chimeric antigen receptor T; TMZL, transformed marginal zone lymphoma; MM, multiple myeloma; NP, not provided; ref, reference; MDRA, Medical Dictionary for Regulatory Activities, version; CTCAE, Common Terminology Criteria for Adverse Events; RS, Richter’ s syndrome; ASTCT, American Society for Transplantation and Cellular Therapy criteria; CARTOX, CAR-T-cell-therapy-associated TOXicity; IWGRC, International Working Group Response Criteria; IMWGRC, International Myeloma Working Group response criteria; IWG on CLL RC, International Workshop Group on CLL response criteria.

Independent scale: the institution used their own criteria instead of international criteria, which can be found in original text.

†Very good partial response was analyzed as complete response.

The statement in original text was severe CRS, but it was not clear if it was ≥ grade 3 and therefore not included for analysis.

*No separate CR and PR numbers were provided.

※Mean ± standard deviation.

#Patients with aggressive (e.g., diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma) or indolent (e.g., follicular lymphoma, marginal zone lymphoma) histologic subtype.

In the original article, the neurotoxicity result of tisa-cel in the Primary Mediastinal B Cell Lymphoma subgroup was incorrectly stated. A correction has been made to Results, Primary Mediastinal B Cell Lymphoma, Paragraph 1.

“A study on tisa-cel that included one patient with PMBCL with central nervous system (CNS) involvement indicated that the patient was showing ongoing response at day 90 and developed only grade 1 CRS and no ICANS”.

Secondly, a percentage was carelessly written incorrectly in the comparison of severe cytokine release syndrome between adult and pediatric patients with acute lymphoblastic leukemia. A correction has been made to Results, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia, Paragraph 3.

“Adult patients with ALL were more likely to develop grade ≥3 CRS than pediatric patients (71 vs 47%, respectively)”.

In addition, we carelessly wrote “tisa-cel” instead of “liso-cel” and used a wrong percentage in one place. A correction has been made to Discussion, Paragraph 5.

“In the TRANSCEND NHL 001 trial, 7% of patients received non-conforming products, two patients experienced manufacturing failure of liso-cel, and 10% of patients died before receiving liso-cel.”

In the original article, there was a mistake in the legend for Figure 8 as published. “tisa-cel” was carelessly written as “axi-cel”. The correct legend appears below.

The forest plots of pooled results in patients with acute lymphoblastic leukemia. (A) The forest plot of complete response rate of tisa-cel. (B) The forest plot of severe cytokine release syndrome rate of tisa-cel. (C) The forest plot of severe immune effector cell-associated neurotoxicity syndrome rate of tisa -cel.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Abramson JS Palomba ML Gordon LI Lunning MA Wang ML Arnason JE . Pivotal Safety and Efficacy Results From Transcend NHL 001, A Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood (2019) 134(Supplement_1):241. doi: 10.1182/blood-2019-127508 Abramson JS Palomba ML Gordon LI Lunning MA Wang M Arnason J . Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study. Lancet (2020) 396:839–52. doi: 10.1016/S0140-6736(20)31366-0